AbbVie Aktie News

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 1 of this series includes AbbVie, Alexandria Real Estate Equities, Arbor Realty Trust, Archer Aviation, and Ares Managemen...

AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers.

AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Current valuation appears stretched, with ABBV stock trading at 23.5x P/E and a PEGY ratio of 1.41x.

Shareholders in both drugmakers appear disappointed that a deal may not happen.

AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines, according to people familiar with the matter. Revolution Medicines has a market value of around $16 billion. It couldn't be learned how much AbbVie is offering, but including a typical deal premium, Revolution could be valued at around $20 billion or more.

NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens.

AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpassing 30% within comparable periods, including significant years such as 2017 and 2024.